Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy, ...

In pulmonary hypertension, a combination of metabolic and mechanical dysfunction leads to irreversible vascular damage.

and pulmonary hypertension may be particularly relevant to the pathophysiology heart failure in patients with preserved ejection fraction, there is compelling rationale for extending the ...

the team saw decreased cardiac pathology. Right ventricular hypertrophy, right ventricular systolic pressure, and vascular remodeling—all complications of pulmonary hypertension—were reduced ...

The 6th World Symposium on Pulmonary Hypertension Task Force on hemodynamic ... into 5 diagnostic categories by shared pathobiology and pathophysiology. 3 This extensive testing, which is required ...

The PAH Initiative is hosting a video event in May to provide information about exercise benefits for PAH patients.

Objectives: To determine the effect of vasopressin therapy on the efficacy of oxygenation and arterial pressure in infants with severe persistent pulmonary hypertension of the newborn. Conclusions ...

Sotatercept improves exercise capacity and delays the time to clinical worsening in patients with World Health Organization (WHO) functional class II or III pulmonary arterial hypertension.

"Pulmonary artery denervation in pulmonary hypertension: A comprehensive meta-analysis" has shed light on the potential of pulmonary artery denervation (PADN) as an innovative intervention for ...

Pulmonary artery denervation in pulmonary hypertension: A comprehensive meta-analysis, has shed light on the potential of pulmonary artery denervation (PADN) as an innovative intervention for ...